In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche, Trimeris in $88mm HIV drug development pact

Executive Summary

Roche and anti-infective therapeutics company Trimeris will together develop Trimeris's anti-HIV fusion inhibitors, T-20 and T-1249. Roche gets US and Canadian co-promotion rights, and exclusive rights in the rest of the world. In exchange, it pays (uf)$10mm in cash up front and granted to Trimeris a warrant to buy 362k shares of common stock at $20.72 each. Trimeris also gets up to $78mm more in developmental, regulatory, and commercial milestones.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies